TG Therapeutics TGTX Proceeds from (Repayments of) Secured Debt
Proceeds from (Repayments of) Secured Debt at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromRepaymentsOfSecuredDebt.
The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about TG Therapeutics's proceeds from (repayments of) secured debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is TG Therapeutics's proceeds from (repayments of) secured debt?
- TG Therapeutics (TGTX) reported proceeds from (repayments of) secured debt of -$255M in Q1 2026.
- What does proceeds from (repayments of) secured debt mean?
- Cash received from or paid toward debt that is backed by assets.
- How do you interpret proceeds from (repayments of) secured debt?
- Proceeds increase liquidity; repayments reduce leverage and interest obligations.
- How does proceeds from (repayments of) secured debt compare across companies?
- Common for companies utilizing asset-backed lending facilities.